Dumping domestic and international health care waste into the earth’s terra firma and oceans undermine global health equity and the health of vulnerable communities.
AMA J Ethics. 2022;24(10):E986-993. doi:
10.1001/amajethics.2022.986.
Denisse Rojas Marquez, MD, MPP and Hazel Lever, MD, MPH
“Very important persons” care contributes to multitiered, racially segregated health service delivery streams that influence clinicians’ conceptions of what patients deserve from them.
AMA J Ethics. 2023;25(1):E66-71. doi:
10.1001/amajethics.2023.66.
Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.
A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
The all-payer rate setting model of pricing combines a uniform payment method with a single rate that all private and public insurers pay for a specific service, thus improving price transparency for patients.
AMA J Ethics. 2015;17(8):770-775. doi:
10.1001/journalofethics.2015.17.8.pfor1-1508.
Decisions about where and to whose professional stewardship patients are admitted are influenced by federal policies of which physicians might not be aware.
AMA J Ethics. 2023;25(12):E901-908. doi:
10.1001/amajethics.2023.901.
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.